SQLite Web: event

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727756-26-000004.txt","as_of":"2026-04-03T11:12:58.166696+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727756-26-000004.txt","company":"VYNE Therapeutics Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727756-26-000004.txt","article_chars":1880,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_548bf13fd73b36cc","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727756-26-000004.txt","content_type":"text/plain","enriched_at":"2026-04-03T12:42:39.964712+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727756-26-000004.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727756-26-000004.txt","source_event_id":"evt_0d3b82f27d8e","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"25ff2b7d414e6488","kind":"sec_filing","published_at":"20260402","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-02","2026-03-31"],"entities":[{"asset_class":"equity","name":"VYNE Therapeutics Inc.","relevance":"high","symbol":"VYNE","type":"company"}],"event_type":"listing","information_gaps":["No details on the total number of shares held by the Chief Scientific Officer before the transaction."],"key_facts":["Form 4 filed on April 2, 2026.","Reporting owner: Stuart Iain, Chief Scientific Officer.","Date of change: March 31, 2026.","Shares withheld for tax withholding requirements: 2,876."],"numeric_claims":[{"label":"Shares withheld for tax","value":"2876"}],"primary_claim":"VYNE Therapeutics Inc. filed a Form 4 on April 2, 2026, reporting stock transactions by the Chief Scientific Officer.","relevance_score":0.7,"sentiment":"neutral","source_quality":"medium","summary":"VYNE Therapeutics Inc. filed a Form 4 on April 2, 2026, disclosing changes related to the Chief Scientific Officer's stock holdings.","topics":["SEC Filing","Insider Trading"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 VYNE Therapeutics Inc. \u00b7 Filed 20260402","ticker":"VYNE","tickers":["VYNE"],"title":"VYNE filed 4","url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727756-26-000004.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — signals

Update row sig_a039291157a8 in signals